Applied Filters
Warner-Lambert: the plausibility test for sufficiency of disclosure
In November, the UK Supreme Court ruled that Warner-Lambert’s patent for a second medical use of pregabalin for the treatment of pain is invalid for insufficiency of disclosure. Sheena Linehan of Potter Clarkson explores the lessons for patent drafting.
Mexico: new links between patents and pharmaceuticals
A new facet of Mexico’s linkage system between patents and pharmaceutical drugs raises several questions that necessitate a careful approach from patent assignees and agents, as Mariana Gonzalez-Vargas of Becerril, Coca & Becerril reports.
Generic competition: when one door closes, another opens
With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.
I-MAK: saving lives by curing the patent system
Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.
SPC waiver: good intentions, but not the right deal?
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports.
USITC: a powerful forum for biologics patent owners
Biologics patent owners should consider the US International Trade Commission as a supplement (or alternative) to district court litigation, say Filko Prugo, Charlotte Jacobsen, Matt Rizzolo and Henry Huang of Ropes & Gray.
A patent attack on three fronts
A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.
Two new weapons for defending Hatch-Waxman litigation
Mark Remus of Brinks Gilson & Lione discusses two patent-related challenges for generic pharmaceutical companies and how they might be overcome.
SPC export waiver: a long road ahead
The European Commission’s proposed export waiver for supplementary protection certificates is likely to face opposition and may be delayed by EU parliamentary changes, says Trevor Cook of WilmerHale.
LSIPR 50 2018: Brian Anderson
Brian Anderson was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
